rsSquibb联系，或致电1-800-FDA-1088与FDA联系，或访问www.fda.gov/medwatch。
包装供应/存储和处理方式
ABECMA装在一个或多个输液袋中（见下文），其中包含一种经转基因的冷冻混悬液。
5％DMSO中修饰的自体T细胞。
每个ABECMA输液袋都单独包装在一个金属盒中。ABECMA储存在蒸气中阶段的液氮，并在液氮干蒸气托运机中提供。内部贴有RFI证书
托运人。
•50毫升输液袋和金属盒（NDC 59572-515-01）
•250毫升输液袋和金属盒（NDC 59572-515-02）
•500毫升输液袋和金属盒（NDC 59572-515-03）
收货后，将患者的身份与卡匣和输液袋上的患者标识符相匹配。
将冷冻的ABECMA储存在液氮的气相中（小于或等于负130°C）。输注前解冻ABECMA[请参阅剂量和用法]。
完整说明资料附件：https://packageinserts.bms.com/pi/pi_abecma.pdf
Bluebird Bio, Inc.US FDA. FDA has accepted Abecma as a cure for adult sufferers with relapsed or refractory multiple myeloma.
Abecma is a custom-made immune cell therapy authorized as a one-time injection with a suggested dose array of 300 to 460 x 106 CAR-positive T cells.
Bluebird Bio disclosed that this journey was started nearly a decade ago and the firm has been endeavoring to bring a new treatment for sufferers living with myeloma. The firm has strived to bring a new approach to fight this disease and this approval of Abecma is the greatest accomplishment of the firm. This approval would mark the first authorized cure in oncology and the first authorized cure in the US of the Bluebird.
|
